REDWOOD CITY, Calif.,
May 20, 2015 /PRNewswire/
-- Genomic Health, Inc. (Nasdaq: GHDX) today announced results
from a study led by the University of
California, San Francisco (UCSF) showing a broad
distribution of Oncotype DX® Genomic Prostate Score (GPS) results
among prostate MRI findings, suggesting that these two technologies
may provide non-overlapping clinical information in men with
localized prostate cancer.
"For the first time, we looked at the association between
information provided by a genomic assay and a prostate MRI to
better understand the value these two technologies bring
to clinical practice," said Michael
Leapman, M.D., lead investigator from UCSF. "These new data
show that, in some patients, further risk stratification may be
possible, and tools such as GPS may add important biological
information to more precisely assess the aggressiveness of a
patient's cancer."
In this study, researchers conducted a retrospective evaluation
of the statistical association between the Oncotype DX GPS results
and contributing gene groups with baseline endorectal MRI in 100
patients with clinically localized prostate cancer. The results
showed a large variation of GPS results across MRI findings,
demonstrating that Oncotype DX and MRI offer non-overlapping
clinical insights in patients with early-stage prostate
cancer.
"The ability to predict whether a man is likely to harbor an
aggressive form of the disease helps guide appropriate treatment
discussion with the patient," said Peter
Carroll, M.D., M.P.H., professor and chair, Department of
Urology, UCSF. "With recent advances in imaging technology and the
availability of a test such as Oncotype DX, physicians now have the
ability to use both anatomical and genomic information to identify
patients for active surveillance, as well as those who may need to
consider an immediate treatment."
These new results follow the recent publication in Urology
Practice of the first decision impact study of the Oncotype DX
prostate cancer test that showed use of the test substantially
increased the number of men who would be eligible for active
surveillance while increasing physician confidence in their
treatment recommendations.
"We believe these results, as well as our recent clinical
utility studies, underscore the value of Oncotype DX in providing
important biologic information to improve risk assessment and
treatment recommendations in patients with newly diagnosed prostate
cancer," said Phil Febbo, M.D.,
chief medical officer, Genomic Health.
About Oncotype DX®
The Oncotype DX® portfolio
of breast, colon and prostate cancer tests applies advanced genomic
science to reveal the unique biology of a tumor in order to
optimize cancer treatment decisions. The Oncotype DX prostate
cancer test identifies which clinically low risk patients are
eligible for active surveillance, as well as those who may benefit
from immediate treatment by predicting disease
aggressiveness. With half a million patients tested in more
than 80 countries, the Oncotype DX testing has redefined
personalized medicine by making genomics a critical part of cancer
diagnosis and treatment. To learn more about the Oncotype DX
prostate cancer test, visit: www.OncotypeDX.com
or www.myprostatecancertreatment.org.
About Genomic Health
Genomic Health, Inc. (NASDAQ:
GHDX) is the world's leading provider of genomic-based diagnostic
tests that address both the overtreatment and optimal treatment of
early-stage cancer, one of the greatest issues in healthcare today.
The company is applying its world-class scientific and commercial
expertise and infrastructure to lead the translation of massive
amounts of genomic data into clinically-actionable results for
treatment planning throughout the cancer patient's journey, from
diagnosis to treatment selection and monitoring. The company
is based in Redwood City, California, with European
headquarters in Geneva, Switzerland. For more
information, please visit, www.GenomicHealth.com and
follow the company on
Twitter: @GenomicHealth, Facebook, YouTube and LinkedIn.
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements relating to the benefits of the test to
physicians, patients and payors. Forward-looking statements are
subject to risks and uncertainties that could cause actual results
to differ materially, and reported results should not be considered
as an indication of future performance. These risks and
uncertainties include, but are not limited to: the ability of test
results to change treatment decisions; the risks and uncertainties
associated with the regulation of the company's tests; the results
of clinical studies; the applicability of clinical study results to
actual outcomes; the risk that the company may not obtain or
maintain sufficient levels of reimbursement, domestically or
abroad, for its existing tests and any future tests it may develop;
the risks of competition; unanticipated costs or delays in research
and development efforts; and the other risks set forth in the
company's filings with the Securities and Exchange Commission,
including the risks set forth in the company's quarterly report on
Form 10-Q for the year ended March 31, 2015. These
forward-looking statements speak only as of the date
hereof. Genomic Health disclaims any obligation to update
these forward-looking statements.
NOTE: The Genomic Health logo, Oncotype, Oncotype
DX, Recurrence Score, and DCIS Score are trademarks or registered
trademarks of Genomic Health, Inc. All other trademarks
and service marks are the property of their respective
owners.
Logo -
http://photos.prnewswire.com/prnh/20130425/SF01493LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/ucsf-led-study-shows-oncotype-dx-and-mri-may-provide-independent-information-in-favorable-risk-prostate-cancer-300086173.html
SOURCE Genomic Health, Inc.